Mr ATORVASTATIN INDUCED ACUTE PANCREATITIS? - A RARE CASE REPORT
Acute pancreatitis is a clinical condition characterized by inflammation of pancreas. The specific time interval to suspect any patient as acute pancreatitis is not clearly defined in any therapeutic guideline and usually symptoms will be lasted for a short period of time. The management of acute pancreatitis always depends on underlying cause. The common medications that can cause acute pancreatitis include angiotensin-converting enzyme inhibitors, azathioprine, and pentamidine. According to the patient case history, abdominal pain was on and off; the patient also received nonsteroidal anti-inflammatory drugs, i.e., tablet aceclofenac 100 mg for abdominal pain, whenever he was experiencing pain and it got subsided only for short period. This case report did not have clear subjective and objective evidence to suspect atorvastatin which was the main culprit of causing acute pancreatitis. The incidence of causing drug-induced acute pancreatitis is very low which was accountable for only 0.1–2%. This case report concludes that all health-care professionals need to have close monitoring of atorvastatin causing acute pancreatitis which is very rarely seen.
2. Vege SS, Yadav D, Chari ST. Pancreatitis. In: Talley NJ, Locke GR, Saito YA, editors. GI Epidemiology. Malden, MA: Blackwell Publishing; 2007.
3. McArthur KE. Review article: Drug-induced pancreatitis. Aliment Pharmacol Ther 1996;10:23-38.
4. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87000.
5. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, atlanta, ga, september 11 through 13, 1992. Arch Surg 1993;128:586-90.
6. Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, et al. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol 1999;25:195-210.
7. Kitamoto Y, Yuan X, Wu Q, McCourt DW, Sadler JE. Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. Proc Natl Acad Sci U S A 1994;91:7588-92.
8. Yamashina I. The action of enterokinase on trypsinogen. Biochim Biophys Acta 1956;20:433-4.
9. Aoun E, Chang CC, Greer JB, Papachristou GI, Barmada MM, Whitcomb DC, et al. Pathways to injury in chronic pancreatitis: Decoding the role of the high-risk SPINK1 N34S haplotype using meta-analysis. PLoS One 2008;3:e2003.
10. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003;67:471-85.
11. Forsmark CE, Baillie J, AGA Institute Clinical Practice and Economics Committee, AGA Institute Governing Board. AGA institute technical review on acute pancreatitis. Gastroenterology 2007;132:2022-44.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.